FDA Approves Genentech’s Lunsumio VELO for Follicular Lymphoma
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Genentech, part of the Roche Group, announced that the U.S. Food and Drug Administration has approved Lunsumio...
